相关实验视频

Updated: Jul 7, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在可切除的N1/N2NSCLC中,新辅助化疗加免疫疗法

Chengli Du¹, Yunhao Chen¹, Yuwei Zhou¹

¹Department of Thoracic Surgery, the first affiliated hospital, Zhejiang University School, 1367 West Wenyi Rd., Hangzhou, 311121, China.

|December 22, 2023

概括

新辅助化疗免疫治疗对于具有阳性淋巴结的局部晚期非小细胞肺癌 (NSCLC) 是安全的. 治疗后的淋巴结清除显著改善了无进展和整体存活率.

科学领域:

在瘤学瘤学.
胸部外科手术胸部外科手术
医学瘤学医学瘤学

背景情况:

具有N1/N2淋巴结转移的局部晚期非小细胞肺癌 (NSCLC) 存在重大生存挑战.
新辅助化疗免疫疗法对这些患者的一小部分提供了好处,但缺乏预测生物标志物.
结节状况对新辅助化疗免疫治疗后生存的影响需要进一步阐明.

研究的目的:

评估新辅助化疗-免疫疗法的安全性和有效性,然后在N1/N2结节转移的可切除NSCLC中进行手术.
确定对新辅助疗法的病理反应的预测因子.
评估病理反应,节点状况和患者生存结果之间的相关性.

主要方法:

对75名可切除的N1/N2期NSCLC患者进行回顾性研究,这些患者正在接受新辅助化学免疫疗法和手术.
收集临床,外科和安全数据.
分析主要病理反应 (MPR),病理完整反应 (pCR),临床因素和存活率 (无进展疾病 (PFS) 和整体存活率 (OS)) 之间的相关性.

主要成果:

与治疗相关的不良反应发生在92%的患者中,10%的患者有3-4级的不良反应.
实现了高的R0切除率 (100%),MPR (60%) 和pCR (36%).
节点清除率为N1患者的67%和N2患者的77%.
高龄和状细胞癌 (SCC) 与更好的病理反应相关;多个淋巴结转移是负面预测因素.
在获得MPR和结节清除的患者中,无进展生存 (PFS) 显着更长.

结论:

术后的新辅助化疗免疫疗法是局部晚期NSCLC与结节转移的安全和可行的方法.
有利的病理反应的预测因素包括老年和SCC组织学,而多个结节转移表明预后较差.
在新辅助疗法后实现淋巴结清除是改善PFS和OS的关键因素.

关键词:

免疫治疗是一种免疫疗法.在本地先进的NSCLCLC.节点状态节点状态病理反应是一种病理反应.幸存者的生存是非常重要的.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...